Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fucose mutarotase is a cytosolic enzyme (EC 5.1.3.29) that catalyzes the reversible interconversion between alpha-L-fucose and beta-L-fucose, two anomeric forms of this essential six-deoxyhexose sugar. This activity is critical for the salvage pathway of GDP-L-fucose biosynthesis, a key donor in cellular fucosylation of glycoproteins and glycolipids. Fucosylated structures are crucial for processes such as cell-cell adhesion, cell recognition, and immune response. In humans, the enzyme is encoded by the FUOM gene; mutations or dysregulation may contribute to congenital disorders of glycosylation and other defects in cell adhesion or metabolism. While not yet established as a direct drug target, fucose mutarotase is under consideration for future therapeutic development due to its central metabolic function and potential disease linkage.
No clinically established drugs; future small-molecule inhibitors or modulators would alter fucose anomer balance and downstream fucosylation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fucose mutarotase (FUOM).